SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Annalisa Pinna, Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued, CNS Drugs, 2014, 28, 5, 455

    CrossRef

  2. 2
    Santiago Perez-Lloret, Marcelo Merello, Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant, Expert Opinion on Pharmacotherapy, 2014, 15, 8, 1097

    CrossRef

  3. 3
    Yoshikuni Mizuno, Tomoyoshi Kondo, Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease, Movement Disorders, 2013, 28, 8
  4. 4
    Rosselle Dungo, Emma D. Deeks, Istradefylline: First Global Approval, Drugs, 2013, 73, 8, 875

    CrossRef

  5. 5
    Patrick Hickey, Mark Stacy, Adenosine A2A Antagonists in Parkinson’s Disease: What’s Next?, Current Neurology and Neuroscience Reports, 2012, 12, 4, 376

    CrossRef

  6. 6
    Fabio Blandini, Marie-Therese Armentero, New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors, Expert Opinion on Investigational Drugs, 2012, 21, 2, 153

    CrossRef

  7. 7
    William Knebel, Niranjan Rao, T. Uchimura, Akihisa Mori, Jeannine Fisher, Marc R. Gastonguay, Philip Chaikin, Population Pharmacokinetic-Pharmacodynamic Analysis of Istradefylline in Patients With Parkinson Disease, The Journal of Clinical Pharmacology, 2012, 52, 10
  8. 8
    Akihisa MORI, S18-3. Strategies of Drug Development for Neurodegenerative Disorders --Development of Antiparkinson Drugs, Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2012, 43, 2, 125

    CrossRef

  9. 9
    Alison Atterbury, Mark J. Wall, A population of immature cerebellar parallel fibre synapses are insensitive to adenosine but are inhibited by hypoxia, Neuropharmacology, 2011, 61, 4, 880

    CrossRef

  10. 10
    Nikoletta Szabó, Zsigmond Tamás Kincses, László Vécsei, Novel therapy in Parkinson's disease: adenosine A2Areceptor antagonists, Expert Opinion on Drug Metabolism & Toxicology, 2011, 7, 4, 441

    CrossRef

  11. 11
    Ignacio Munoz-Sanjuan, Gillian P. Bates, The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease, Journal of Clinical Investigation, 2011, 121, 2, 476

    CrossRef

  12. 12
    Mattia Veronese, Alessandra Bertoldo, Shrinivas Bishu, Aaron Unterman, Giampaolo Tomasi, Carolyn Beebe Smith, Kathleen C Schmidt, A spectral analysis approach for determination of regional rates of cerebral protein synthesis with the L-[1-11C]leucine PET method, Journal of Cerebral Blood Flow & Metabolism, 2010, 30, 8, 1460

    CrossRef

  13. 13
    Paul LaBeaume, Ma Dong, Michail Sitkovsky, Elizabeth V. Jones, Rhiannon Thomas, Sara Sadler, Amy E. Kallmerten, Graham B. Jones, An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives, Organic & Biomolecular Chemistry, 2010, 8, 18, 4155

    CrossRef

  14. 14
    Micaela Morelli, Nicola Simola, Patrizia Popoli, Anna R. Carta, Handbook of Basal Ganglia Structure and Function, 2010,

    CrossRef

  15. 15
    Micaela Morelli, Anna R. Carta, Anil Kachroo, Michael A. Schwarzschild, Recent Advances in Parkinson’s Disease: Basic Research, 2010,

    CrossRef

  16. 16
    P. Jenner, A. Mori, R. Hauser, M. Morelli, B.B. Fredholm, J.F. Chen, Adenosine, adenosine A2A antagonists, and Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, 6, 406

    CrossRef